BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses

Irit Avivi; Efrat Luttwak; Esther Saiag; Tami Halperin; Shira Haberman; Ariel Sarig; Sivan Levi; Anat Aharon; Yair Herishanu; Chava Perry

doi:10.1111/bjh.18029

BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses

Irit Avivi^*, Efrat Luttwak, Esther Saiag, Tami Halperin, Shira Haberman, Ariel Sarig, Sivan Levi, Anat Aharon, Yair Herishanu, Chava Perry

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine booster in 44 B-cell non-Hodgkin lymphoma (B-NHL) patients who failed to respond to two prior doses [42 previously exposed to anti-CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti-CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B-NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B-NHL that completed anti-CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.

Original language	English
Pages (from-to)	1329-1333
Number of pages	5
Journal	British Journal of Haematology
Volume	196
Issue number	6
DOIs	https://doi.org/10.1111/bjh.18029
State	Published - Mar 2022

Keywords

B-cell non-Hodgkin lymphoma
BNT162b2
COVID-19 vaccine booster
humoral response

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.18029

Cite this

Avivi, I., Luttwak, E., Saiag, E., Halperin, T., Haberman, S., Sarig, A., Levi, S., Aharon, A., Herishanu, Y., & Perry, C. (2022). BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses. British Journal of Haematology, 196(6), 1329-1333. https://doi.org/10.1111/bjh.18029

@article{24672fbe4ccc4b1ba8b42b283bf932fd,

title = "BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses",

abstract = "This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine booster in 44 B-cell non-Hodgkin lymphoma (B-NHL) patients who failed to respond to two prior doses [42 previously exposed to anti-CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti-CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B-NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B-NHL that completed anti-CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.",

keywords = "B-cell non-Hodgkin lymphoma, BNT162b2, COVID-19 vaccine booster, humoral response",

author = "Irit Avivi and Efrat Luttwak and Esther Saiag and Tami Halperin and Shira Haberman and Ariel Sarig and Sivan Levi and Anat Aharon and Yair Herishanu and Chava Perry",

note = "Publisher Copyright: {\textcopyright} 2022 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2022",

month = mar,

doi = "10.1111/bjh.18029",

language = "אנגלית",

volume = "196",

pages = "1329--1333",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

Avivi, I, Luttwak, E, Saiag, E, Halperin, T, Haberman, S, Sarig, A, Levi, S, Aharon, A , Herishanu, Y & Perry, C 2022, 'BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses', British Journal of Haematology, vol. 196, no. 6, pp. 1329-1333. https://doi.org/10.1111/bjh.18029

TY - JOUR

T1 - BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses

AU - Avivi, Irit

AU - Luttwak, Efrat

AU - Saiag, Esther

AU - Halperin, Tami

AU - Haberman, Shira

AU - Sarig, Ariel

AU - Levi, Sivan

AU - Aharon, Anat

AU - Herishanu, Yair

AU - Perry, Chava

PY - 2022/3

Y1 - 2022/3

N2 - This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine booster in 44 B-cell non-Hodgkin lymphoma (B-NHL) patients who failed to respond to two prior doses [42 previously exposed to anti-CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti-CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B-NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B-NHL that completed anti-CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.

AB - This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine booster in 44 B-cell non-Hodgkin lymphoma (B-NHL) patients who failed to respond to two prior doses [42 previously exposed to anti-CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti-CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B-NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B-NHL that completed anti-CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.

KW - B-cell non-Hodgkin lymphoma

KW - BNT162b2

KW - COVID-19 vaccine booster

KW - humoral response

UR - http://www.scopus.com/inward/record.url?scp=85123499023&partnerID=8YFLogxK

U2 - 10.1111/bjh.18029

DO - 10.1111/bjh.18029

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35075635

AN - SCOPUS:85123499023

SN - 0007-1048

VL - 196

SP - 1329

EP - 1333

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this